Matrix Science Pharma (MSP)

ABSTRACT

Coronavirus disease 2019 (COVID‑19): A plague which has impacted health and economy worldwide on an exceptional scale. Patients have diverse clinical outcomes, but those with preexisting cardiovascular disease, hypertension, and related conditions sustain strangely worse outcome. Hypertension is a significant risk factor of mortality worldwide and it has been focused more nowadays because of its association with novel coronavirus 2 (severe acute respiratory syndrome coronavirus 2 [SARS‑CoV‑2]) infection mentioned as COVID‑19. Patients showing severe COVID‑19 infections mostly seen to be older and had a history of hypertension. Most of the patients who have died within the pandemic were known cases of hypertension. This article demonstrates the relation between angiotensin‑converting enzyme 2 (ACE2) and COVID‑19 with its possible mechanisms. Hence, with this review, we have raised multiple questions regarding a more severe course of COVID‑19 in regard to hypertension itself and thus the antihypertensives used. With the data available, it is quite clear that the infection is understood to be caused by the SARS‑CoV‑2 and is responsible for human‑to‑human transmission of disease, entering the cells through its predicated receptor ACE2.